Literature DB >> 8222411

Allograft salvage of failed total elbow arthroplasty. A report of two cases.

G D Foulkes1, M M Mitsunaga.   

Abstract

Infection after total elbow arthroplasty (TEA) is a devastating complication. Current management options include (1) salvage of the implant with debridement and parenteral antibiotics, (2) resection arthroplasty, and (3) arthrodesis. Most infected TEA patients ultimately require resection arthroplasty. Inadequate bone may preclude both revision TEA and successful resection arthroplasty. It is in these cases that the patient may benefit from allograft reconstruction. Two patients with painful flail elbows secondary to previous resection arthroplasties were treated successfully with cadaver allograft augmented with in situ autograft. Use of the allograft resulted in improvement from failure to excellent in this patient with posttraumatic arthrosis at five years after operation and from failure to good in a rheumatoid patient at two years after operation. Autograft-augmented allografts in the resected failed-TEA patient are a valuable and bone-preserving option. This may be especially useful in patients with significant bone loss or young patients with posttraumatic arthrosis, for whom arthrodesis may be the only other surgical option. The method should not preclude further revision TEA.

Entities:  

Mesh:

Year:  1993        PMID: 8222411

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  2 in total

1.  Osteoarticular and total elbow allograft reconstruction with severe bone loss.

Authors:  F Daniel Kharrazi; Benjamin T Busfield; Daniel S Khorshad; Francis J Hornicek; Henry J Mankin
Journal:  Clin Orthop Relat Res       Date:  2008-01-03       Impact factor: 4.176

2.  Impaction Grafting in Revision Total Elbow Arthroplasty for Aseptic Loosening and Bone Loss: Surgical Technique.

Authors:  Yong Girl Rhee; Nam Su Cho; Chong Suck Parke
Journal:  JBJS Essent Surg Tech       Date:  2013-09-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.